There is increasing interest in developing 3D tumor organoid models for drug development and personalized medicine approaches. While tumor organoids are in principle amenable to high-throughput drug screenings, progress has been hampered by technical constraints and extensive manipulations required by current approaches. Here, we introduce a miniaturized, fully automatable, flexible high-throughput method using a simplified geometry to establish 3D organoids from cell lines and primary tumors and robustly assay drug responses.
performed two consecutive treatments which allows the drugs to not only penetrate the gel but also reach organoids that may be bulky 12 . However, the assay is flexible; single drug treatments, more consecutive recurring treatments as well as multi-drug combinations can also be performed (Fig. S3 ).
Assays for cell viability based on staining of live organoids with specific dyes followed by imaging are also feasible.
We optimized a calcein release assay coupled to propidium iodide (PI) staining and a caspase 3/7 cleavage assay ( Fig. 1e-g and S4) . Both are performed upon seeding the cells in standard black plates. Tumor organoids are stained with the reagents after dispase release and neutralization. After a 30-45 minutes incubation, organoids are imaged with a Celigo S cell imager. Images are then segmented and quantified ( Fig. 1e-g and S4) . As the organoids are assayed in the same well in which they are seeded, it is important to determine which assay/plate to use beforehand.
Although the assays are testing different biological events, results are concordant across the methods (Fig. 1, S4 and   S5 ).
Most importantly, the miniring approach offers the possibility to perform multiple assays on the same plate/set of samples. For example, we coupled the ATP metabolic assay to 3D tumor count and total area measurement. We did so while testing suitability of the approach to identify drug susceptibilities of primary ovarian cancer samples obtained from the operating room. We used one patient-derived cell line, S1 GODL 18 , to optimize conditions ( Fig. S5 ) and two ovarian cancer patient samples (Table S1 and Fig. 2 ). We optimized the initial seeding cell number and selected 5000 cells/well in order to obtain a low enough number of organoids for size distribution analysis but sufficient to measure an ATP signal by CaspaseGlo 3D. We prepared six 96 well plates and tested 252 different kinase inhibitors at two different concentrations for each patient (120 nM and 1 µM). We used the same experimental paradigm optimized above. All steps (media change, drug treatment) were automated and performed in less than 2 minutes/plate using a Beckman Coulter Biomek FX integrated into a Thermo Spinnaker robotic system. At the end of the experiment, PDTOs were first imaged in brightfield mode for organoid count/size distribution analysis followed by ATP assay. We observed a high degree of equivalence between outcomes from the two methods ( Fig. 2a and c) .
Results highlight individual sensitivities to different drugs ( Fig. 2a-g ). The three samples tested showed minimal overlap in their response to kinase inhibitors (Fig. 2g) .
Cells obtained from Patient #1 at the time of cytoreductive surgery 18 were chemo-naïve, and the heterogeneous nature of this clear cell/HGSC tumor is fully recapitulated in the PDTOs (Fig. 1b) . The organoids were sensitive to 16/252 molecules tested and responded mostly to a variety of cyclin-dependent kinase (CDK) inhibitors (Fig. 2a-c) .
Interestingly, CDK inhibitors have found limited applicability in ovarian cancer therapy so far 19 . Based on the profiles of the CDK inhibitors tested and on the response observed ( Fig. S5b-c) , we selected four untested molecules to assay.
We anticipated that Patient #1 should not respond to Palbociclib (targeting CDK4/6) and THZ1 (CDK7) while expecting a response to JNJ-7706621 (CDK1/2/3/4/6) and AZD54338 (CDK1/2/9; Fig. S5b-c) . However, we observed a strong response to THZ1 but no response to JNJ-7706621 (Fig. 2h) . Interestingly, both THZ1 and BS-181 HCl specifically target CDK7, however Patient #1 PDTOs showed a strong response to the former but no response to the latter which could be attributed to the different activity of the two as recently observed in breast cancer 20 .
Cells were obtained from Patient #2, a heavily pre-treated patient diagnosed with progressive, platinum-resistant HGSC (Table S1) . PDTOs only showed a strong response to 3/252 drugs tested, with sensitivity to two of these (BGT226, a PI3K/mTOR inhibitor and Degrasyn, a deubiquitinases inhibitor) shared with all other tested samples (Fig.   2c, 2f and S5a). Moderate responses (50-60% residual cell viability at 1 µM) were observed for EGFR inhibitors and we could detect high expression of EGFR at the plasma membrane of the tumor cells (Fig. S5e) . Remarkably, Patient #2 PDTOs showed a very moderate response to our positive control, Staurosporine, a pan-kinase inhibitor with very not peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission.
The copyright holder for this preprint (which was . http://dx.doi.org/10.1101/138412 doi: bioRxiv preprint first posted online Jun. 28, 2017; broad activity 21 . We anticipated that the lack of response to multiple therapies may be due to over-expression of efflux membrane proteins. In fact, Patient #2 PDTOs showed a high level of expression of ABCB1 (Fig. 2i) . High-expression of the ATP-dependent detox protein ABCB1 is frequently found in chemoresistant ovarian cancer cells and recurrent ovarian patients' samples and has been correlated with poor prognosis 22,23 .
In conclusion, the miniring approach can be a robust tool to standardize precision medicine efforts, given its ease of applicability to many different systems and drug screening protocols as well as limited cell requirement which allows testing of samples as obtained from biopsies/surgical specimens without the need for expansion. As demonstrated above, the method rapidly allowed to pinpoint drug sensitivities in tumor samples and allowed us to identify a tumor "fingerprint", with multiple inhibitors converging on a given pathway. However, we observed that different drugs targeting the same protein or molecular pathway gave rise to varying responses. In addition, some of the drugs identified in our screening do not have a specific, unequivocal predictive biomarker or genomic signature. Thus, patients may greatly benefit from PDTO testing prior to therapy selection 6, 8 .
This method can be successfully used to test samples that do not easily grow as patient-derived xenografts (PDX) in vivo. In fact, Patient #1 cells injected in NSG mice (500K/mouse, 12 mice) did not give rise to detectable tumor masses over four weeks (data not shown). Complete automation, scalability to 384 well plates, and flexibility to use different supports beside Matrigel can further extend applicability of the miniring approach.
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Chemicals: Doxorubicin hydrochloride was purchased from Sigma (#44583). Staurosporine was purchased from Cell
Signaling Technology (#9953S). ReACp53 was synthesized by GL Biochem and prepared as described 3 .
3D organoids seeding/treatment procedure: Single-cell suspensions (2K-10K/well) were plated around the rim of the well of 96 well plates in a 3:4 mixture of PrEGM medium and Matrigel (BD Bioscience CB-40324). White plates (Corning #3610) were used for ATP assays while black ones (Corning #3603) were used for caspase or calcein assays. Plates are incubated at 37°C with 5% CO 2 for 15 minutes to solidify the gel before addition of 100 µl of prewarmed PrEGM to each well using an EpMotion (Eppendorf). Two days after seeding, medium is removed and replaced with fresh PrEGM containing the indicated drugs. The same procedure is repeated twice in two consecutive days. 24h after the last treatments, media is removed and wells are washed with 100 µl of pre-warmed PBS.
Organoids are then released from Matrigel for downstream experiments by 40 minutes of incubation in 50 µl of 5mg/mL dispase (Life Technologies #17105-041). All steps are performed with the EpMotion for small scale experiments and medium is removed/added from the center of the wells. For the high-throughput kinase screening experiment, we utilized a Beckman Coulter Biomek FX system with 96 channel head integrated into a Thermo Spinnaker robotic system with Momentum scheduling software. In short, an intermediary dilution plate (Axygen P-96-450V-C-S) was filled with 100 µl/well of media and pre-warmed to 37°C. Using pre-sterilized p50 tips, 1 µl of drug is transferred from a library compound plate to the intermediary media plate and thoroughly mixed. Next, the robot gently removed 100 µl of media from the matrigel/cell plate. The liquid handler was set up to hit the dead center of well with no contact to the Matrigel miniring. As a last step, the robot transferred 100 µl from the intermediary plate (media+drug) to the matrigel/cell plate. Media was easily dispensed without touching or disrupting the Matrigel miniring. The total process time outside of the CO 2 incubator was less than 2 so that the temperature was controlled throughout.
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